阿利西尤单抗对无症状家族性高胆固醇血症患者冠状动脉粥样硬化的影响:ARCHITECT研究
ARCHITECT是一项IV期、开放标签、多中心、单臂临床试验,评估阿利西尤单抗联合高强度他汀治疗78周对无临床动脉粥样硬化性心血管疾病的家族性高胆固醇血症患者冠状动脉斑块负荷及特征的影响。104例患者完成研究,冠状动脉斑块负荷从34.6%降至30.4%(P<0.001),斑块特征向钙化和纤维化转变,提示斑块稳定。
要点
- 阿利西尤单抗联合高强度他汀治疗78周可显著降低家族性高胆固醇血症患者冠状动脉斑块负荷。
- 治疗还促进斑块稳定,表现为纤维化和钙化成分增加,纤维脂肪和坏死成分减少。
- 该研究为阿利西尤单抗在无症状家族性高胆固醇血症患者中的斑块逆转和稳定作用提供了影像学证据。
核心结论
- 在无临床动脉粥样硬化性心血管疾病的家族性高胆固醇血症患者中,阿利西尤单抗联合高强度他汀治疗78周可显著逆转冠状动脉斑块负荷并促进斑块稳定。
研究设计与样本
- IV期、开放标签、多中心、单臂临床试验,纳入无临床动脉粥样硬化性心血管疾病的家族性高胆固醇血症患者,接受阿利西尤单抗150 mg每14天皮下注射联合高强度他汀治疗,基线和78周行冠状动脉CT血管造影。
- 104例患者完成研究,中位年龄53.3(46.2-59.4)岁,女性54例(51.9%)。
主要发现
- 中位低密度脂蛋白胆固醇从基线138.9(117.5-175.3)mg/dL降至随访时45.0(36.0-65.0)mg/dL(P<0.001)。
- 冠状动脉斑块负荷从基线34.6%(32.5%-36.8%)降至随访时30.4%(27.4%-33.4%)(P<0.001)。
- 斑块特征显著改变:钙化斑块比例增加(+0.3%;P<0.001),主要为纤维斑块比例增加(+6.2%;P<0.001),纤维脂肪斑块比例减少(-3.9%;P<0.001),坏死斑块比例减少(-0.6%;P<0.001)。
临床怎么用
- 对于无临床动脉粥样硬化性心血管疾病的家族性高胆固醇血症患者,在最大耐受剂量他汀(±依折麦布)基础上加用阿利西尤单抗可能有助于斑块逆转和稳定。
局限性
- 本研究为单臂、开放标签设计,无对照组,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, on coronary plaque burden in patients with familial hypercholesterolemia has not been addressed. Our aim was to assess changes in coronary plaque burden and its characteristics after treatment with alirocumab by quantification and characterization of atherosclerotic plaque throughout the coronary tree on the basis of a noninvasive analysis of coronary computed tomographic angiography in asymptomatic subjects with familial hypercholesterolemia receiving optimized and stable treatment with maximum tolerated statin dose with or without ezetimibe. METHODS: This study is a phase IV, open-label, multicenter, single-arm clinical trial to assess changes in coronary plaque burden and its characteristics after 78 weeks of treatment with alirocumab in patients with familial hypercholesterolemia without clinical atherosclerotic cardiovascular disease. Participants underwent an initial coronary computed tomographic angiography at baseline and another at 78 weeks. Every patient received 150 mg of alirocumab subcutaneiously every 14 days in addition to high-intensity statin therapy. The main outcome was the change on coronary plaque burden and its characteristics by quantification and characterization of atherosclerotic plaque throughout the coronary tree on the basis of analysis of coronary computed tomographic angiography. RESULTS: The study was completed by 104 patients. The median age was 53.3 (46.2-59.4) years. Of these patients, 54 were women (51.9%). Median low-density lipoprotein cholesterol was 138.9 (117.5-175.3) mg/dL at entry and 45.0 (36.0-65.0) mg/dL at follow-up (P<0.001). Coronary plaque burden changed from 34.6% (32.5%-36.8%) at entry to 30.4% (27.4%-33.4%) at follow-up (P<0.001). A significant change in the characteristics of the coronary atherosclerosis was also found: an increase in the proportion of calcified (+0.3%; P<0.001) and mainly fibrous (+6.2%; P<0.001) plaque, accompanied by a decrease in the percentage of fibro-fatty (-3.9%; P<0.001) and necrotic plaque (-0.6%; P<0.001). CONCLUSIONS: Treatment with alirocumab in addition to high-intensity statin therapy resulted in significant regression of coronary plaque burden and plaque stabilization on coronary computed tomographic angiography over 78 weeks in these groups of patients with familial hypercholesterolemia without clinical atherosclerotic cardiovascular disease. ARCHITECT (Effect of Alirocumab on Atherosclerotic Plaque Volume, Architecture and Composition) could link and explain ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) results. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT05465278.
引用
- Pérez de Isla, Díaz-Díaz, Romero, et al. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study. Circulation. 2023. PMID: 37009731. doi:10.1161/CIRCULATIONAHA.122.062557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。